MedTrace Logo

Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis

NCT02326103 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-01-19

No results posted yet for this study

Summary

The study is aimed to evaluate the additional role of ciprofloxacin therapy in severe alcoholic hepatitis combined to prednisolone therapy in an open-label placebo controlled manner.

Conditions

  • Alcoholic Hepatitis
  • Alcoholic Cirrhosis

Interventions

DRUG

Ciprofloxacin

Comparison of ciprofloxacin with placebo in alcoholic hepatitis

DRUG

Placebo

Sponsors & Collaborators

  • University of Helsinki

    lead OTHER

Principal Investigators

  • Perttu Sahlman, MD · University Hospital of Helsinki

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02326103 on ClinicalTrials.gov